Carbocisteine 750mg/10ml oral solution 10ml sachets sugar free

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Carbocisteine

Tilgjengelig fra:

Esteve Pharmaceuticals Ltd

ATC-kode:

R05CB03

INN (International Name):

Carbocisteine

Dosering :

75mg/1ml

Legemiddelform:

Oral solution

Administreringsrute:

Oral

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 03070000; GTIN: 5039021000152

Informasjon til brukeren

WHAT IS IN THIS LEAFLET
1.
What Carbocisteine oral solution in sachet is and
what it is used for
2.
What you need to know before you take
Carbocisteine oral solution in sachet
3.
How to take Carbocisteine oral solution in
sachet
4.
Possible side effects
5.
How to store Carbocisteine oral solution in
sachet
6.
Contents of the pack and other information
1.
WHAT CARBOCISTEINE ORAL SOLUTION
IN SACHET IS AND WHAT IT IS USED FOR
This medicine belongs to a group of medicines
called “mucolytics”. It works by making mucus
(phlegm) less sticky. This makes the mucus easier
to cough up. This medicine is used for problems
with the breathing passages (respiratory tract).
This medicine is indicated in adults and children
over 15 years.
2.
WHAT YOU NEED TO KNOW BEFORE
YOU TAKE CARBOCISTEINE ORAL
SOLUTION IN SACHET
DO NOT TAKE CARBOCISTEINE ORAL SOLUTION IN SACHET:
- if you are allergic to carbocisteine or any of the
other ingredients contained in Carbocisteine oral
solution in sachet,
- if you have an ulcer in your stomach or gut
(small intestine).
When in doubt, you should always consult a doctor
or pharmacist.
PLEASE TAKE SPECIAL CARE WITH CARBOCISTEINE ORAL
SOLUTION IN SACHET:
Consult your doctor immediately:
•
if you have thick, purulent sputum or fever,
•
if you suffer from chronic illness (long-term) of
the bronchi or lungs,
•
if you are elderly,
•
if you have had an ulcer in your stomach or gut,
•
if you are taking other medicines known to cause
bleeding in the gut.
PRECAUTIONS FOR USE
This medicine should always be accompanied by
voluntary efforts to cough, which help
expectoration.
Do not take cough medicine (to stop coughing) or
medicine that dries out bronchial secretions during
the treatment period with carbocisteine.
CONSULT A DOCTOR IF NO IMPROVEMENT IS SEEN.
OTHER MEDICINES AND CARBOCISTEINE ORAL SOLUTION
IN SACHET
Tell your doctor or pharmacist if you are taking,
have recently taken or might take any other
medicines, even if it is medication obtained without
a prescription.
This medicine contains ca

Preparatomtale

OBJECT 1
CARBOCISTEINE 750MG/10ML SUGAR-FREE ORAL
SOLUTION IN SACHET
Summary of Product Characteristics Updated 19-Nov-2017 | Intrapharm
Laboratories Limited
1. Name of the medicinal product
Carbocisteine unither pharmaceuticals 750mg/10ml sugar-free oral
solution in sachet
Carbocisteine 750mg/10ml sugar-free oral solution in sachet
2. Qualitative and quantitative composition
Each 10 ml of oral solution contains 750 mg of carbocisteine
Excipients with known effect:
sodium methyl para-hydroxybenzoate (E 219) 15mg per dose
sorbitol liquid (non-crystallising) 1.3g per dose
maltitol, liquid 1.3g per dose
sodium 97.5mg per dose
ethanol (trace)
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Oral solution in sachet.
Limpid, viscous, light brown solution.
4. Clinical particulars
4.1 Therapeutic indications
This medicine is indicated in adults and children over 15 years for
the adjunctive therapy of respiratory
tract disorders characterised by excessive, viscous mucus, including
chronic obstructive airways disease.
4.2 Posology and method of administration
FOR ADULTS AND CHILDREN OVER 15 YEARS ONLY
Oral route.
One 10 ml sachet contains 750 mg of carbocisteine.
The standard dose is 750 mg, 3 times a day (i.e. 2250mg), or 1 sachet,
3 times a day. The dose should be
reduced to 1500mg daily in divided doses when a satisfactory response
is obtained i.e. dose reduction
from 3 sachets per day to 2 sachets per day (taken separately).
This medicine is appropriate for patients following a low sugar or low
calorie diet.
4.3 Contraindications
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section 6.1.
Active peptic ulceration
4.4 Special warnings and precautions for use
Special warning
Productive coughs that represent a fundamental element in
bronchial-pulmonary defences should be
respected.
The association of bronchial mucous modifiers with anti-cough
medicines and/or substances that dry out
secretions (atropinic) is not rational.
This medicine contains sodium methyl para-